📰 Beyond RET Inhibitors: New Targets Emerging in RET+ Lung #Cancer. @mihaela_aldea / @AriMarinel / @RETpositive . Read publication:

New data in pancreatic #cancer!. The NEOPAN Phase III trial led by Prof. Michel Ducreux (@GustaveRoussy) shows FOLFIRINOX improves PFS vs gemcitabine in LAPC, with similar OS and QoL. 👉 #PancreaticCancer #OncoResearch #FOLFIRINOX

🎤 With Quentin Blampey, PhD – expert in spatial data science. ⏳ Don’t miss this opportunity to engage live and ask your questions!.👉 Register here: . #SpatialOmics #Bioinformatics #SpatialTranscriptomics.

🚨Few days left!. Join us this Friday, May 16 at 13:30 (Paris time) for a deep dive into computational methods for spatial omics analyses. 🔍 Discover how Sopa and Novae, two open-source powerfool tools for spatial transcriptomics research. ⬇

📸 Photo : © @ahmsab_MD on X.

📰 New ERN-EuroBloodNet guidelines for adult Burkitt lymphoma now published in The Lancet Haematology. First EU-wide recommendations to harmonise diagnosis, risk-adapted treatment & prognosis. 🔗 #Lymphoma #Haematology

📢 New publication from @GustaveRoussy researchers & collaborators in Nature Cancer further supports the tumor-agnostic indication of pembrolizumab ! 📢. Read the study:

📣 We are excited to announce the first scientific day on liquid biopsy, organized by @GustaveRoussy and the @PrismCenter, taking place on June 11, 2025, in Paris! 🧬🔬. 🔗 More information & registration:

📰 Low-dose gut radiation enhances immunotherapy. New #research shows it boosts PD-L1 blockade, triggering a stronger systemic anti-tumor immune response. The gut microbiome plays a key role—this could be a game-changer for #cancer treatment. #Immunotherapy #Oncology #PDL1

RT @GustaveRoussy: 📰 Des chercheurs parviennent à reproduire une leucémie pédiatrique à partir de cellules humaines non-cancéreuses. L’équ….

📰 “De-escalation in Lung Cancer Treatment: Are We Ready?”. A new review in JCO explores de-escalation strategies for ICBs in NSCLC—reducing dose, duration, or frequency—to cut toxicity, costs, and improve global access without compromising efficacy. 🔗

📰 @GustaveRoussy Authorised to Conduct Phase I Clinical Trials in Nuclear Medicine. 🎯 The Institute can now evaluate innovative radioligands administered for the first time or at an early stage in humans. More informations 👉

RT @barlesi: 🚀 Congrès IFODS 2025 🚀. 📄 Retrouvez tous les détails dans le programme ci-dessous et via la page : ….

🎯 IFODS 2025, le rendez-vous de l’oncologie française !. ⤵⤵⤵.

Congrès IFODS 2025 🚀. 📅 Le 12/06/2025, lors du Congrès National d’Oncologie - IFODS, nous vous donnons rendez-vous pour une session Présidentielle : IFODS - Gustave Roussy », qui se déroulera sous la présidence de Fabrice Barlesi, Francoise Mornex et Jean-Philippe SPANO. ⤵

📰 Le Dr Elie Rassy, oncologue médical au sein du comité de pathologie mammaire de @GustaveRoussy et co-investigateur d’ETNA, revient en cinq questions sur cet essai clinique. 🔗

🚀 Join us at the inaugural AI in Oncology 2025 Conference ! 🚀. 📅 June 17-18, 2025.📍 Paris, France.🌍 Bringing together top researchers, clinicians, and industry leaders. 🔗 Register now and be part of the conversation:

📰 We are thrilled to share our paper in Nature Reviews Cancer: "The Evolutionary Theory of Cancer: Challenges and Potential Solutions" by Lucie Laplane (@GustaveRoussy) and Carlo Maley (@ASU). Read the full paper here ⤵

📰 This study published in @radiology_rsna, led by researchers from @GustaveRoussy, aimed to evaluate tumor fraction (TF) in liquid biopsy as a potential surrogate for total tumor volume (TTV) measured on CT across 1,065 patients with metastatic cancer. 🔗

📢 @criscancer and @GustaveRoussy are partnering to offer an exciting opportunity for a talented early career clinician scientist to develop their academic skills and expertise. 🗓️ Deadline open until 28 February. ⬇ ⬇ ⬇.